AMAZING blog on the important role ED providers play in recognizing the nuances that go into the managing AF in patients on ibrutinib! 👏🏻 Awesome job @iEMPharmD
One of my FAVORITE #cardioonc topics!
Summary of the 🔑 considerations 👇🏻
Clinical conundrum: ibrutinib interferes with each pillar of AF management
Risk scoring tools (CHADS2VASC OR HASBLED) NOT validated in cancer patients‼️
Ibrutinib: Inhibitor 🆇 of PGP & substrate of CYP3A4➡️DDI💊
Ibrutinib ⤴️bleeding risk ALONE & only further in pts on AC
Overall, difficult clinical conundrum, how do we maintain the therapeutic benefit of ibrutinib while ⤵️toxicities⚠️?
As Craig mentioned,🆕BTK inhibitors may ⬇️ risk, BUT data w/acalabrutinib still shows signals of AF risk&bleeding is on-target BTK effect so risk remains
#Oncopharm this blog post shows the importance of us educating beyond our own speciality to raise awareness on the unique toxicities and management strategies for new cancer therapies!
Last week I had one of my final presentations of the year! With a catchy title😉
Urine for an Update! Updates in the management of metastatic urothelial cancer
Hold your bladders, this is an extensive update! 😂 #oncopharm
Bladder cancer can be divided into two ✌️subtypes: 1) Non-muscle invasive: encompasses in-situ and localized disease➡️5-yr OS >70%
2) Muscle invasive: encompasses regional or metastatic disease➡️5-yr OS dismal especially for metastatic disease 😔
Cisplatin=SOC
50% of pts w are ineligible due to older age👵🏻, poor PS, ⬇️ renal function, ⬇️hearing, neuropathy, heart failure 🫀& other comorbities that ⬆️ risk of ⚠️
Carboplatin yields inferior responses➡️NOT 🙅🏻♀️ an equal alternative due to ⬇️ OS😢➡️pt left w/minimal tx options
What medications 💊 are should be avoided 🛑 or used with caution ⚠️ in patients with Myasthenia Gravis? 🤔
See 👀 the thread 🧵below⤵️ that summarizes an amazing grand rounds presentation by @UKPharmRes PGY1 @AliW_PharmD on key 🔑 medication considerations in MG
1️⃣Antibiotics to avoid or use w/caution🦠 💊
🛑FQs = FDA BBW for ⤴️ risk of MG crisis ➡️ avoid use if possible
⚠️ Macrolides ⤴️ rate of MG crisis (case reports)
⚠️ AG linked to ⤴️ ICU acquired weakness & exacerbate ‼️ MG crisis
📝Risk⬆️ w/neomycin vs. tobramycin & amikacin
Antibiotics considered to be SAFE alternatives to the above include
✅Beta-lactams
✅Tetracyclines
✅Linezolid
✅Bactrim
Ex. In an MG patient who presents 🏥 w/CAP 🫁 ➡️ choose ceftriaxone + doxycycline✅ OVER ceftriaxone + azithromycin🛑